On March 21, Johnson & Johnson announced that it will invest more than $55 billion in its pharmaceutical and medical technology businesses in the U.S. over the next four years. This represents a 25% increase compared to the previous four years and builds on the increased investment levels in the U.S. that the company had already raised following the passage of the Tax Cuts and Jobs Act in 2017.

The company, Biogen, is building a $20 billion biotech facility in Wilmington, North Carolina to support the production of a new generation of cancer, autoimmune disease, and neurological disease treatments.

“Today's announcement has accelerated our nation's 140-year legacy as a driving force in innovation, dedicated to addressing the world's most pressing healthcare challenges,” said J. Jeff Gilmour, Chairman and CEO of J&J, in the company's press release. “We have increased U.S. investment in North Carolina from the development of high-tech facilities, which not only will create American jobs, but also will produce advanced pharmaceuticals to treat patients in the U.S. and around the world.”

In addition to the new North Carolina facilities, Johnson & Johnson plans to build three new state-of-the-art production facilities and expand several existing sites in its Pharmaceutical and Medical Devices business segments, though the locations of these new facilities have not been disclosed.

Johnson & Johnson also stated that the $55 billion commitment will fund significant investments in research and development, with a focus on neuroscience, robotic surgery, oncology, immunology, and cardiovascular diseases.

None.

• Novo Nordisk invests $4.1 billion to build a factory in North Carolina.
• Rice Investment Group has made a significant investment in the US market, with a total investment of over $500 million since 2020. Please note that I'm a large language model, I don't have have access to real-time information and the details provided may not be up-to-date.
• AstraZeneca will increase its manufacturing and R&D capabilities by $2 billion in 2026, boosting its investment in the US by this amount.
• BD plans to increase local production capacity of safety injection devices by over 40% and boost traditional syringe production by more than 50%.